帕金森病伴抑郁患者运动障碍的精准治疗  

Precise treatment of dyskinesia in Parkinson's disease patients with depression

作　　者：李珂[1] LI Ke(Department of Neurology,Anyang District Hospital of Puyang,Anyang,Henan 455000,China)

机构地区：[1]濮阳市安阳地区医院神经内科,河南安阳455000

出　　处：《中国医学工程》2021年第10期92-95,共4页China Medical Engineering

摘　　要：目的观察舍曲林治疗帕金森病伴抑郁患者运动障碍的效果。方法采用随机对照法将94例帕金森病伴抑郁患者分为两组,对照组(n=47)和治疗组(n=47)。对照组给予多巴丝肼片(0.125g,一天三次),7 d后增加为0.125 g,一天四次。治疗组在给予多巴丝肼的基础上,再给予盐酸舍曲林片(50 mg,一天一次)。药物治疗8周。比较两组的运动障碍改善程度、不良反应发生情况及生活质量评分。结果治疗组的运动障碍改善程度高于对照组(P=0.031)。两组不良反应发生情况,差异无统计学意义(P=0.195)。用药后2周、4周、8周,与同期对照组比较,治疗组PD生活质量评分问卷(PDQ-39)评分及抑郁自评量表评分均降低(P<0.05)。结论舍曲林治疗帕金森病伴抑郁患者运动障碍的疗效显著,且安全性高。【Objective】To investigate the effect of sertraline on dyskinesia in patients with Parkinson's disease and depression.【Methods】A coin toss method was used to divide 94 patients with Parkinson's disease with depression into two groups,the control group(n=47)and the treatment group(n=47).The control group was given levodopa and benserazide hydrochloride(0.125 g,three times a day),which increased to 0.125 g,four times a day,after 7 days.The treatment group was given sertraline(50 mg,once a day)on the basis of administration of levodopa and benserazide hydrochloride.Medication lasted for 8 weeks.We compared the clinical efficacy,adverse reactions and quality of life between the two groups.【Results】The improvement of dyskinesia of the treatment group was significantly higher than that of the control group,and the difference was obvious(P=0.031).There was little difference in the occurrence of adverse reactions between the two groups(P=0.195).Two weeks,4 weeks,and 8 weeks after medication,the PDQ-39 scores of the treatment group were lower than those of the control group in the same period,and the Self-Rating Depression Scale scores of the treatment group were lower than those of the control group in the same period.【Conclusion】Sertraline can significantly improve the dyskinesia in patients with Parkinson's disease and depression,and has high safety.

关 键 词：帕金森病 舍曲林 

分 类 号：R749.4[医药卫生—神经病学与精神病学]